Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision®), a pilot study

Table 2 Backgrounds of the patients for analysis

		All patient (n = 41)	With CIPN (n = 28)	Without CIPN (n = 13)
Age		55.8 ± 11.0	57.0 ± 10.7	53.2 ± 11.6
Cancer type	Ovarian	22	16	6
	Cervical	11	5	6
	Endometrial	8	7	1
Regimen	TC ± BV	34	27	7
	TP	5	1	4
	PTX + NED	2	0	2
Cycle		5.9 ± 0.4	5.9 ± 0.3	5.7 ± 0.7
Body-surface area (m²)		1.484 ± 0.126	1.472 ± 0.121	1.509 ± 0.137
Cumulative PTX dose (mg/m²)		1000.6 ± 101.3	1028.5 ± 38.6	940.8 ± 158.6
Cumulative Platinum dose (mg/m²)	CBDCA	2328.9 ± 305.5	2340.7 ± 294.5	2283.6 ± 366.7
	CDDP	514.8 ± 112.4	296	331.8 ± 35.1
	NED	604.0 ± 5.7	-	400

Values are indicated as means ±standard deviations
PTX paclitaxel, CBDCA carboplatin, CDDP cisplatin, NED nedaplatin, TC ± BV bevacizumab (15 mg/kg) ± paclitaxel (175 mg/m²) + carboplatin (AUC = 6), TP paclitaxel (175 mg/m²) + cisplatin (75 mg/m²), PTX-NED paclitaxel (175 mg/m²) + nedaplatin (80 mg/m²)

ISSN: 2055-0294